Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8154780 | 1.00 | RAB9A (0.51) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL20601970 | 1.00 | RAB9A (0.51) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL8154779 | 1.00 | RAB9A (0.51) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL9682651 | 0.81 | RAB9A (0.49) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL9682645 | 0.81 | RAB9A (0.49) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL8647851 | 0.76 | RAB9A (0.45) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL11636581 | 0.75 | CCR6 (0.33) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL11636584 | 0.75 | CCR6 (0.33) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL12813288 | 0.72 | RAB9A (0.42) | RAB9AALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL12813289 | 0.72 | RAB9A (0.42) | RAB9AALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0007582-B1 | COMPOSITIONS AND PROCESS FOR REINFORCING, MODIFYING OR IMPROVING THE ORGANOLEPTIC PROPERTIES OF TOBACCO PRODUCTS AND COMPOUNDS USEFUL THEREFOR | L. GIVAUDAN & CIE Société Anonyme (CH) | 1981-11-25 | — | — | EP | claimed |
| EP-0007582-A2 | Compositions and process for reinforcing, modifying or improving the organoleptic properties of tobacco products and compounds useful therefor | L. GIVAUDAN & CIE Société Anonyme (CH) | 1980-02-06 | — | — | EP | claimed |
| US-4183363-A | Tobacco compositions flavored with 2-hydroxymethylenecyclohexanones | GIVAUDAN CORPORATION (US) | 1980-01-15 | — | — | US | claimed |
| EP-2768307-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9499464-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140256782-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2768307-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013072882-A1 | 2 -AMINO- 1, 8 -NAPHTHYRIDINE-3 -CARBOXAMIDE DERIVATIVES AS ANTIMICROBIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013058809-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012134971-A2 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011155983-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-4313007-A | ENHANCING ORGANOLEPTIC PROPERTIES OF TOBACCO | GIVAUDAN CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
| EP-0007582-B1 | COMPOSITIONS AND PROCESS FOR REINFORCING, MODIFYING OR IMPROVING THE ORGANOLEPTIC PROPERTIES OF TOBACCO PRODUCTS AND COMPOUNDS USEFUL THEREFOR | L. GIVAUDAN & CIE Société Anonyme (CH) | 1981-11-25 | — | — | EP | disclosed |
| EP-0007582-A2 | Compositions and process for reinforcing, modifying or improving the organoleptic properties of tobacco products and compounds useful therefor | L. GIVAUDAN & CIE Société Anonyme (CH) | 1980-02-06 | — | — | EP | disclosed |
| US-4183363-A | Tobacco compositions flavored with 2-hydroxymethylenecyclohexanones | GIVAUDAN CORPORATION (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | CRYAB, CRYAA, PDE6C | RAB9A 1250/4885ALDH1A1 2166/4885MAPT 1097/4885 |
| US-20140256782-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, PDE6C, CRYAA | RAB9A 1160/4885ALDH1A1 2291/4885MAPT 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.